Evaluation of Omarigliptin (MK-3102) in Obese Participants and in Participants With Type 2 Diabetes (MK-3102-004)

NCT01088711 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

32

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes (T2D)

Interventions

DRUG: Omarigliptin
DRUG: Placebo

Sponsor

Merck Sharp & Dohme LLC